A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Melanoma, Herpetic Infection
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
-
Corazon United States of America, LLC doing business as Life Clinical Trials, Coral Springs, Florida, United States, 33076
Mercy Medical Center, Baltimore, Maryland, United States, 21202
Jefferson City Medical Group PC, Jefferson City, Missouri, United States, 65109
TriHealth Cancer Institute - Kenwood, Cincinnati, Ohio, United States, 45242
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States, 15213
Allegheny Health Network, Pittsburgh, Pennsylvania, United States, 15224
University of Tennessee Medical Center, Knoxville, Tennessee, United States, 37920
Intermountain Medical Center, Murray, Utah, United States, 84107
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States, 53792
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Amgen,
MD, STUDY_DIRECTOR, Amgen
2038-01-07